Antineoplastic busulfan encapsulated in a metal organic framework nanocarrier: first in vivo results

Abstract

Nanoparticles of a mesoporous iron(III) trimesate MIL-100 nanocarrier encapsulating high amounts of the challenging antineoplastic busulfan were administered to rats and compared with the commercial Busilvex®. Large differences in serum concentration of both busulfan and trimesate revealed the great impact of drug encapsulation both on the drug and on nanoparticle pharmacokinetics during the first 24 h of administration.